BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giorgi H, Ammerman J, Briffaux J, Fretellier N, Corot C, Bourrinet P. Non-clinical safety assessment of gadoterate meglumine (Dotarem®) in neonatal and juvenile rats. Regulatory Toxicology and Pharmacology 2015;73:960-70. [DOI: 10.1016/j.yrtph.2015.09.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Khairinisa MA, Takatsuru Y, Amano I, Erdene K, Nakajima T, Kameo S, Koyama H, Tsushima Y, Koibuchi N. The Effect of Perinatal Gadolinium-Based Contrast Agents on Adult Mice Behavior. Invest Radiol 2018;53:110-8. [PMID: 28915162 DOI: 10.1097/RLI.0000000000000417] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
2 Turk O, Ozdemir NG, Atci IB, Saygi T, Yilmaz H, Antar V. Intraventricular Gadoteric Acid Intoxication: First Report. World Neurosurg 2018;111:264-8. [PMID: 29292188 DOI: 10.1016/j.wneu.2017.12.130] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Runge VM. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents. Invest Radiol 2017;52:317-23. [PMID: 28368880 DOI: 10.1097/RLI.0000000000000374] [Cited by in Crossref: 92] [Cited by in F6Publishing: 28] [Article Influence: 23.0] [Reference Citation Analysis]
4 Bussi S, Penard L, Bonafè R, Botteron C, Celeste R, Coppo A, Queliti R, Kirchin MA, Tedoldi F, Maisano F. Non-clinical assessment of safety and gadolinium deposition after cumulative administration of gadobenate dimeglumine (MultiHance®) to neonatal and juvenile rats. Regul Toxicol Pharmacol 2018;92:268-77. [PMID: 29278694 DOI: 10.1016/j.yrtph.2017.12.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
5 McDonald JS, McDonald RJ. MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis. Magn Reson Imaging Clin N Am 2020;28:497-507. [PMID: 33040991 DOI: 10.1016/j.mric.2020.06.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
6 Zhang L, Liu Y, Zhang Q, Li T, Yang M, Yao Q, Xie X, Hu HY. Gadolinium-Labeled Aminoglycoside and Its Potential Application as a Bacteria-Targeting Magnetic Resonance Imaging Contrast Agent. Anal Chem 2018;90:1934-40. [PMID: 29293308 DOI: 10.1021/acs.analchem.7b04029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
7 Mcdonald RJ, Mcdonald JS, Dai D, Schroeder D, Jentoft ME, Murray DL, Kadirvel R, Eckel LJ, Kallmes DF. Comparison of Gadolinium Concentrations within Multiple Rat Organs after Intravenous Administration of Linear versus Macrocyclic Gadolinium Chelates. Radiology 2017;285:536-45. [DOI: 10.1148/radiol.2017161594] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 19.8] [Reference Citation Analysis]
8 Baldrick P. Nonclinical safety testing of imaging agents, contrast agents and radiopharmaceuticals. J Appl Toxicol 2021;41:95-104. [PMID: 32833236 DOI: 10.1002/jat.4054] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Runge VM. Dechelation (Transmetalation): Consequences and Safety Concerns With the Linear Gadolinium-Based Contrast Agents, In View of Recent Health Care Rulings by the EMA (Europe), FDA (United States), and PMDA (Japan). Invest Radiol 2018;53:571-8. [PMID: 30130320 DOI: 10.1097/RLI.0000000000000507] [Cited by in Crossref: 34] [Cited by in F6Publishing: 3] [Article Influence: 11.3] [Reference Citation Analysis]